MOG35-55-biotin – Mouse
Biotin-MOG (35-55) peptide is the biotinylated version of Mouse MOG (35-55) peptide which is used to induce the Experimental Autoimmune Encephalomyelitis (EAE) mouse model for T-cell-mediated inflammatory demyelinating autoimmune diseases of the CNS.
MOG35-55 – MEVGWYRSPFSRVVHLYRNGK – CAS 163913-87-9
Myelin oligodendrocyte glycoprotein (MOG) is a type I integral membrane glycoprotein of the immunoglobulin superfamily (Ig) found exclusively in mammals. The 26-28 kDa protein is located on the external surface of the oligodendrocyte membrane,mostly on the peripheral lamellae of myelin sheaths of the Central nervous system (CNS)1.
MOG35-55 for EAE induction
The immunodominant 35-55 epitope of MOG (MOG 35-55) is a primary target for both cellular and humoral immune responses1. Anti-MOG antibodies and the abnormal activation of encepalitogenic T cells upon recognition of MOG (35-55) peptide cause the destruction of myelin sheath during Multiple sclerosis (MS),a common inflammatory autoimmune disorder of the CNS1. Although MOG is a minor component of the CNS,the 35-55 epitope of MOG (MOG 35-55) is strongly immunogenic and therefore is widely used for in vivo biological evaluation and immunological studies of the Experimental Autoimmune Encephalomyelitis (EAE),a mouse animal model for T-cell-mediated inflammatory demyelinating autoimmune diseases of the CNS1.
Administration of MOG35-55 peptide in mice produces anti-MOG antibodies that cause demyelination and a chronic Experimental Autoimmune Encephalomyelitis1.
Anti-MOG antibodies are observed in cerebrospinal fluid (CFS) and the serum of MS pateints. There is a direct correlation between the severity of the MS symptomes and anti-MOG titers. The progression of Multiple sclerosis is rapid and relapses occur more frequently in presence of anti-MOG antibodies. Therefore,anti-MOG antibodies are an indicator for the prognosis and progression of Multiple sclerosis1. They can be detected by MOG (35-55) epitope-coated ELISA for quantification.
MOG (35-55)-induced EAE models can help elucidating the immunopathological mechanism of Multiple sclerosis and promote the developement of novel therapeutics. One therapeutic approach consists on the administration of a mixture of peptides,representing immunodominant epitopes of different myelin proteins including MOG peptide at a proper dose to modulate the immune response and induce tolerance1.
Also available: Ready to use syringes with pre-emulsified MOG35-55/CFA EAE induction kit
Click here to discover SB-PEPTIDE’s Human MOG peptides pool for T-cells activation
Technical specification
| Sequence : Biotin-MEVGWYRSPFSRVVHLYRNGK | |
| MW : 2808 ,25 g/mol (C128H191N37O31S2) | |
| Purity : > 95% | |
| Counter-Ion : TFA Salts (see option TFA removal) | |
| Delivery format : Freeze dried in propylene 2 mL microtubes | |
| Other names : Biotinylated Myelin Oligodendrocyte Glycoprotein peptide (35-55) | |
| Peptide Solubility Guideline | |
| Bulk peptide quantities available |
Price
| Product catalog | Size | Price € HT | Price $ USD |
| SB283-1MG | 1 mg | 198 | 248 |
Quote request
If you are interested in ordering this product,please ask for a quote and we will get back to you shortly.